To evaluate the potential of KATP inhibitors for the treatment of migraine, it therefore seems important to develop new drugs selective for the Kir6.1/SUR2B subtype due to its dominant presence in vascular tissue. This evidence concerns the gene KCNJ8 and migraine disorder.